Lower respiratory tract infections (LRTI) are the most common bacterial infections among patients in intensive care units (ICUs) occurring in 10-25% of all ICU patients and resulting in high overall mortality, which may range from 22-71%. [1,2] Most common bacterial agents of LRTI in the ICU are Pseudomonas, Acinetobacter, Klebsiella, Citrobacter, Escherichia coli. [3][4] [5] In almost all cases, there is a need to initiate empirical antimicrobial treatment before obtaining the microbial results, but the situation 
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is further complicated by the emergence of multiple beta lactamase producers and multidrug resistant pathogens. In a recent report, Infectious Disease Society of America, specifi cally addressed three categories of gram negative bacilli (GNB), namely extended spectrum beta lactamase (ESBL) producing Escherichia coli, and Klebsiella spp., Multidrug resistant (MDR) Pseudomonas, and carbapenem resistant Acinetobacter spp., as high priority bacterial pathogens. [6] All these major reports indicate the need for obtaining data on prevalent strains in the ICU along with the susceptibility pattern, to help in revising antibiotic policy and guiding clinicians for the better management of patients. Prevalent fl ora and antimicrobial resistance pattern may vary from region to region depending upon the antibiotic pressure in that locality. Therefore, the present study was designed to know the bacterial profi le and determine the antimicrobial resistance pattern among the aerobic GNB isolated from LRT of patients admitted to the ICU of our institute.
Materials and Methods
The present retrospective study was conducted in the Microbiology department of a teaching tertiary care hospital during Jan-Dec 2007. Transtracheal or bronchoscopic aspirates collected aseptically from 207 patients of all age and sex groups requiring mechanical ventilation for at least three days were included in study. All samples were plated right after the collection and were further processed as per standard protocol. [7] Single or mixed growth (two or more than two isolates per specimen) isolated from all the eligible consecutive samples were identifi ed by observing the colony characteristic on the blood, Mac-Conkey agar plate and biochemical reactions using standard microbiological methods. [7] Isolates from repeat culture of previously recruited patients and isolates identifi ed as commensals or contaminants were excluded. Susceptibility testing was done by Disc diffusion method. [8] The following antibiotics (Hi-Media Disc in mcg) were tested: Amikacin(Ak) (30), ciprofl oxacin(Cf) (5), ofl oxacin (Of) (5), aztreonam (Ao) (30), netilmicin (Nt) (30), doxycycline (Do) (30), cotrimoxazole (co) (25), ceftazidime (Cz) (30), ceftizoxime (Ck) (30), meropenem (Mr) (10), amoxycillin/ clavulanic acid (Ac) (20/10), piperacillin/tazobactum (TZP) (100/10). Zone diameter was measured and interpreted as per the Clinical and Laboratory Standards Institute (CLSI) guidelines. For quality control of disc diffusion tests ATCC control strains of E. coli ATCC 25922, S. aureus ATCC 25923 and P. aeruginosa ATCC 27853 strains were used.
Statistical analysis
For retrospective analysis, SPSS software was used for calculation of percentage resistance of 95% confi dence interval (CI).
Results
During the study period, laboratory data of 207 patients whose LRT specimens were received in our laboratory was evaluated. Male to female ratio was 1.8:1. Out of the 207 patients, 70 were from the surgical ward, 62 from urology, 35 from medicine, 28 from nephrology, 12 from neuromedicine. Out of 207 specimens, 144 (69.5%) were culture positive whereas, 63 (30.43%) specimens showed no growth. From the 144 culture positive specimens, 161 isolates were recovered. Out of 161 isolates, 154 (95.6%) were GNB, three (1.86%) were Candida spp., and four (2.4%) were Gram positive cocci.
In 17 (11.0%) specimens, there were two isolates per specimen and 127 (82.4%) specimens showed growth of a single organism. Table 1 represents the distribution of micro organisms recovered from the LRT specimens of ICU patients. The most common GNB in order of frequency were P. aeruginosa (35%), Acinetobacter baumannii (23.6%) and Klebsiella pneumoniae (13.6%). Very high rate of resistance (60-100%) was observed among A. baumannii and K. pneumoniae isolates to ceftazidime, amoxyclav, ciprofl oxacin, amikacin, and cotrimoxazole. Meropenem and doxycycline were the most effective in vitro drugs against A. baumannii, K. pneumoniae, and Enterobacter [ Table 2 ]. P. aeruginosa isolates showed high rate of resistance to aztreonam (94.7%), netilmicin (70.2%), ceftazidime (68.4%), ceftizoxime (68.4%), and ofl oxacin (68.4%) [ Table 2 ]. Out of 57 isolates of P. aeruginosa, 23 (40%) were resistant to all the antibiotics used against P. aeruginosa in the panel. Meropenem was the most effective (77.2%) drug in vitro followed by piperacillin/ tazobactum combination (50.5%) [ Table 2 ]. Bacterial resistance rates (%R 95% CI) to doxycycline for various isolates except P. aeruginosa are given in Table 3 .
Discussion
Pneumonia is a frequent complication in patients admitted to the ICU. It is frequently polymicrobial with predominently multi drug resistant GNB, such as A. baumannii, P. aeruginosa, K. pneumoniae, E. coli. [7, 9, 10] In our study, 97.4% isolates were GNB. P. aeruginosa (35%) being the most common isolate followed by A. baumannii (23.6%) and K. pneumoniae. In 10.75% cases, two isolates were recovered from a single specimen, in contrast to the other study that reported two to three isolates per specimen in 16.3% cases. [5] Antibiotic resistance is a major problem in ICU admitted patients. We noticed 100%, 96.9%, and 68.4% resistance to ceftazidime against A. baumannii, Klebsiella spp. and P. aeruginosa, respectively. Similar observations were made by other investigators that reported 96-100% resistance; [11, 12] whereas, other workers have reported lower rate of resistance (37-67.5%) to ceftazidime. [11, 13] High rate of resistance at our center might be due to the selective influence of extensive usage of third generation cephalosporins. Carbapenems are frequently used as a last choice in treating serious infections caused by GNB. In our study, 25.6% isolates of Acinetobacter spp., 22.8% isolates of P. aeruginosa, and 9% isolates of Klebsiella spp., were resistant to meropenem in contrast to another study, where meropenem resistance was found in 14.2% isolates of A. baumannii and 12-42.5% isolates of P. aeruginosa, respectively. [4, 14] Another study reported 100% sensitivity to meropenem against Klebsiella spp.
[ 15] This fi nding suggests that meropenem should be used judiciously in ventilated patients to prevent any further increase in resistance to meropenem. Another important observation of our study was that doxycycline, an old drug not included in empirical treatment in ICUs, nowadays had shown good sensitivity against A. baumannii, Klebsiella spp., Enterobacter spp., E. coil, and Citrobacter spp. [ Table 3 ]. Vila et al., reported 98% sensitivity to doxycycline among A. baumannii. [16] We observed that 33% isolates of A. baumannii were sensitive and 64.4% strains were intermediate sensitive (IS) to doxycycline. Intermediate sensitive strains are amenable to treatment when large doses of the drug are used. [17] We did not perform MIC of IS strains, since this is a retrospective analysis of laboratory data and strains were not preserved for further study. Further studies are required to evaluate the usefulness of doxycycline for ICU admitted patients.
Limits and outcome
One of the potential limitations of this study is that epidemiologic analysis, ESBL phenotypic detection and MIC of doxycycline was not carried out. Despite this limitation our data can be used for local therapeutic choices.
We conclude that nonfermenters are the most common etiological agents of LRTIs in ICU. There is an alarmingly high rate of resistance to cephalosporins, ␤ lactam-␤-lactamase inhibitors, and carbapenem against predominant organisms. We suggest that further studies should be carried out to evaluate the usefulness of doxycycline against the ICU pathogens. Judicious use of older and newer antimicrobial agents is essential to prevent the emergence of multi drug resistant bacteria in the ICU. 
